ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.
about
A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHDOverview of Attention Deficit Hyperactivity Disorder in Young ChildrenLong-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challengesMeta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adultsClinical practice: Adult attention deficit-hyperactivity disorderFrom Clinical Application to Cognitive Enhancement: The Example of MethylphenidatePractitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescentsRisk of stroke in prescription and other amphetamine-type stimulants use: A systematic review.Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.Twin and sibling studies using health insurance data: the example of attention deficit/hyperactivity disorder (ADHD).Safety of non-therapeutic atomoxetine exposures--a national poison data system study.The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration.Data management and data analysis techniques in pharmacoepidemiological studies using a pre-planned multi-database approach: a systematic literature review.Norepinephrine transporter function and human cardiovascular disease.Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.Complications and continuation of intrauterine device use among commercially insured teenagers.Classification of Therapeutic and Experimental Drugs for Brown Adipose Tissue Activation: Potential Treatment Strategies for Diabetes and ObesityA systematic review of the safety of lisdexamfetamine dimesylate.Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.Methylphenidate off-label use and safety.Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?Adult ADHD Medications and Their Cardiovascular ImplicationsAmphetamines, atomoxetine and the risk of serious cardiovascular events in adults.An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adultsOff-label use of atomoxetine in adults: is it safe?Exercise outcomes in prevalent users of stimulant medications.High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case reportPrescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects.Risk of methylphenidate-induced prehypertension in normotensive adult smokers with attention deficit hyperactivity disorder.Case definitions for acute myocardial infarction in administrative databases and their impact on in-hospital mortality rates.Efficacy and safety of atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorderTargeting presynaptic norepinephrine transporter in brown adipose tissue: a novel imaging approach and potential treatment for diabetes and obesity.Understanding the treatment of attention deficit hyperactivity disorder in newly diagnosed adult patients in general practice: a UK database studyUse of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries.Depression treatment in patients with coronary artery disease: a systematic review.Attention deficit hyperactivity disorder and athletes.Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes.Adult attention deficit hyperactivity disorder: translating research into practice.Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
P2860
Q24632726-01E82FE9-7AB2-4F87-A117-217357564677Q26765839-844E2BCE-9C9D-4C67-BE0D-04EA5FD0F03DQ26822392-72C22BFE-61A4-4F83-BC7C-D0369BAB446CQ26858868-545D0032-4F9E-45E3-AE0D-94ECF870B23FQ27027395-0CCAB93B-762B-4F2B-889E-4C2954597B89Q28073785-677512A5-DDAD-40AF-8576-8A58AA807680Q28282770-C03D1E08-3002-4BE1-B622-91AF41FE1839Q30234520-3A01D56E-5E74-43EE-B37E-03D3507CED74Q30399107-7E4CCBFD-5428-428D-85DE-D7D3332E391BQ30620838-54C87C55-7AEA-4A33-8E3A-8C6CB4E145D4Q30655656-EACA2A9B-487C-45ED-B6E2-F2D2C60DEA48Q30925195-DF8A1554-3EED-4E76-9264-DD7964D61EFBQ30980437-D05DC17A-87D0-4855-AA37-E8AC7A84B0ACQ33161828-D079037E-73B4-4173-BEAC-CA95F6E14A81Q33165982-66A7A59C-EF84-4C32-A88D-C51B4D7CBA6FQ33640994-004E16AC-3D20-4190-88FC-51F5E289FB46Q33659194-AF777F32-061E-4842-B506-99512121FCDEQ33755396-DF040AF8-82AF-457A-B96C-CB53388C8A6FQ34063584-252314FA-D225-4900-B2DC-9A0C4F844CCEQ34172165-D5E6A3E6-38F4-45A7-921E-71D561309A1CQ34280107-CB22D6CF-0769-43C6-80D0-0BF9CED1E1C2Q34461113-65AD68DA-6173-4598-B5BC-3B9BEEEC0643Q34539026-EB8CDA2F-382C-44AC-83C2-745F491E038EQ34575150-3836E9A6-7296-4F81-B132-DCC45674D1DCQ34603303-D4EB2C52-423C-49E1-AB78-3BDB0E8DDA84Q34618993-B6709010-837F-4642-B581-48C59C9D8711Q35624268-C3D8D3A0-5946-4968-A0BC-A9775CBC729BQ36125316-AB06D58C-4533-4D86-9D89-B0546A7D1E0FQ36373539-0A01F3D9-63FC-46B4-8C20-7DA46404D405Q36567686-767E1566-BF11-42D9-9AE2-9C7A1D9EB956Q36661519-041EAF5A-29C3-4606-A72E-64995FC2E415Q36751226-A79A44AF-D989-4795-81B5-CA4716D48ADBQ37256662-FB92D600-5785-4CA5-A7C7-132CA0EC172DQ37300928-332E1068-E6DC-47F1-801F-7948D84C62CCQ37416392-E8F99D7D-DD76-473F-8D6B-061329856D4BQ37533862-1506F713-6B59-45C4-9E15-F685CB01B0F8Q37596910-6A5FEC73-AB6D-47CF-B814-D5E9C75390FAQ37722786-8CDCD4D1-1FE3-4D10-B661-0DC86123FC83Q37986704-28B189C2-6244-40FB-96C3-FC1FBD000C01Q38060572-F5E80D92-C762-457E-8EBD-B80729005A2D
P2860
ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
ADHD medications and risk of s ...... n young and middle-aged adults
@nl
ADHD medications and risk of s ...... young and middle-aged adults.
@ast
ADHD medications and risk of s ...... young and middle-aged adults.
@en
ADHD medications and risk of s ...... young and middle-aged adults.
@en-gb
type
label
ADHD medications and risk of s ...... n young and middle-aged adults
@nl
ADHD medications and risk of s ...... young and middle-aged adults.
@ast
ADHD medications and risk of s ...... young and middle-aged adults.
@en
ADHD medications and risk of s ...... young and middle-aged adults.
@en-gb
prefLabel
ADHD medications and risk of s ...... n young and middle-aged adults
@nl
ADHD medications and risk of s ...... young and middle-aged adults.
@ast
ADHD medications and risk of s ...... young and middle-aged adults.
@en
ADHD medications and risk of s ...... young and middle-aged adults.
@en-gb
P2093
P2860
P50
P3181
P356
P1476
ADHD medications and risk of s ...... n young and middle-aged adults
@en
P2093
Bruce H Fireman
Connie Uratsu
David H Smith
Denise M Boudreau
Joe V Selby
Mai N Nguyen-Huynh
Marsha A Raebel
Ninah Achacoso
Pamala A Pawloski
P2860
P304
P3181
P356
10.1001/JAMA.2011.1830
P407
P577
2011-12-12T00:00:00Z